**S2 Table.** Median, 1st and 3rd quartiles for estimated growth rates and LAI/MAI using the logistic growth model.

|  |  |  |  |
| --- | --- | --- | --- |
| 　 | Median | 1st quartile  | 3rd quartile |
| Primary growth rate | 0.280  | 0.160  | 0.417  |
| Metastatic growth rate | 1.159  | 0.610  | 1.767  |
| Primary growth rate during GEM | 0.157  | -0.024  | 0.280  |
| Metastatic growth rate during GEM | 0.915  | 0.119  | 1.322  |
| Primary growth rate during FFX | -0.022  | -0.181  | 0.203  |
| Metastatic growth rate during FFX | 0.934  | 0.474  | 1.116  |
| Primary growth rate during GEM+nab-paclitaxel | 0.052 | -0.081 | 0.300 |
| Metastatic growth rate during GEM+nab-paclitaxel | 1.420  | 0.479  | 1.732 |
| LAI | 0.586  | 0.299  | 1.075  |
| MAI | 0.452  | 0.138  | 1.675  |

\*The time unit for growth rates is 1/month.

P-values using the Mann-Whitney test for comparing primary growth rates.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Regimen | No-treatment | GEM | GEM+nab-paclitaxel | FFX |
| No-treatment |  |  |  |  |
| GEM | p<0.001 |  |  |  |
| GEM+nab-paclitaxel | p<0.001 | 0.261 |  |  |
| FFX | p<0.001 | p<0.001 | 0.0472 |  |

P-value using the Mann-Whitney test for comparing metastatic growth rates.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Regimen | No-treatment | GEM | GEM+nab-paclitaxel | FFX |
| No-treatment |  |  |  |  |
| GEM | 0.00108 |  |  |  |
| GEM+nab-paclitaxel | 0.098 | 0.00981 |  |  |
| FFX | p<0.001 | 0.0482 | 0.00172 |  |

\*P-values were adjusted using the Benjamini-Hochberg procedure to account for multiple testing.